LRRK2

ESCAPE Bio to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 19, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, LRRK2, SVB Leerink, Companies, Economy of the United States, ESCAPE Bio, ESB1609, LRRK2 Parkinson’s Disease

ESCAPE Bio, Inc. , a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020.

Key Points: 
  • ESCAPE Bio, Inc. , a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020.
  • Location: Lotte New York Palace in New York, NY
    Ms. Smith will present program and corporate updates.
  • ESCAPE recently initiated a Phase 1 multiple ascending dose study in healthy volunteers with ESB1609 and toxicology studies with their G2019S LRRK2 inhibitor.
  • ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases.

Leucine Rich Repeat Serine Threonine Protein Kinase 2, Pipeline Review, H2 2019 - Central Nervous System, Cardiovascular, Oncology & Ophthalmology - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Enzymes, Protein kinases, LRRK2, Serine/threonine-specific protein kinase, Protein kinase, LRRK1, PAK6

The "Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Pipeline Review, H2 2019'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules.
  • Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene.
  • The report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease

Retrieved on: 
Tuesday, January 14, 2020
Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, LRRK2, Pharmacology

We are pleased with the continued progress across our pipeline, including a significant step forward for our LRRK2 program with encouraging clinical data in patients and healthy subjects for two molecules, said Ryan Watts, Ph.D., CEO.

Key Points: 
  • We are pleased with the continued progress across our pipeline, including a significant step forward for our LRRK2 program with encouraging clinical data in patients and healthy subjects for two molecules, said Ryan Watts, Ph.D., CEO.
  • Denali intends to select either DNL201 or DNL151 in mid-2020 to advance into Phase 2/3 clinical trials in patients with Parkinsons disease.
  • This study ( NCT04056689 ) is a 28-day, multicenter, randomized, placebo controlled, double-blind Phase 1b clinical trial in patients with mild-to-moderate Parkinsons disease.
  • The forward-looking statements in this press release are based on information available to Denali as of the date hereof.

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website

Retrieved on: 
Wednesday, September 4, 2019
Branches of biology, Biology, LRRK2, Parkinson, The Parkinsons, MTOR

LRRK2 is a regulator of lysosomal function, which is impaired in Parkinsons disease and may be restored by LRRK2 inhibition.

Key Points: 
  • LRRK2 is a regulator of lysosomal function, which is impaired in Parkinsons disease and may be restored by LRRK2 inhibition.
  • Inhibition of LRRK2 activity may potentially slow the progression of disease in all patients with Parkinsons disease based on restoration of lysosomal function.
  • The launch of our Engage Parkinsons website is intended to strengthen our engagement and interactions with the Parkinsons disease patient community.
  • EngageParkinsons.com The Denali Parkinsons disease patient engagement website provides patients, caregivers, healthcare professionals, and advocates an online destination for emerging information about Parkinsons disease.

BERG Presents Clinical Target Validation Data for the Treatment of Parkinson's Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018

Retrieved on: 
Wednesday, November 7, 2018
Biology, Cell biology, Biochemistry, Neuroscience, Transcription factors, Proteins, LRRK2, Neurodegeneration, P53, MTOR

Pre-clinical data identifying promising molecules and pathways as target candidates for major depressive disorder.

Key Points: 
  • Pre-clinical data identifying promising molecules and pathways as target candidates for major depressive disorder.
  • Pre-clinical metabolic signaling data with potential to distinguish between age-related changes in the brain and age-related cognitive decline in Alzheimer's disease.
  • In vitro data suggesting mechanistic link between leucine-rich repeat kinase 2 (LRRK2), p53 inducible gene 3 (PIG3) and PD-related neurodegeneration.
  • Neurometabolomic and phenotype data supportive of PIG3 as a novel therapeutic target in PD-specific pathologies.

BERG Presents Clinical Target Validation Data for the Treatment of Parkinson's Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018

Retrieved on: 
Wednesday, November 7, 2018
Biology, Cell biology, Biochemistry, Neuroscience, Transcription factors, Proteins, LRRK2, Neurodegeneration, P53, MTOR

Pre-clinical data identifying promising molecules and pathways as target candidates for major depressive disorder.

Key Points: 
  • Pre-clinical data identifying promising molecules and pathways as target candidates for major depressive disorder.
  • Pre-clinical metabolic signaling data with potential to distinguish between age-related changes in the brain and age-related cognitive decline in Alzheimer's disease.
  • In vitro data suggesting mechanistic link between leucine-rich repeat kinase 2 (LRRK2), p53 inducible gene 3 (PIG3) and PD-related neurodegeneration.
  • Neurometabolomic and phenotype data supportive of PIG3 as a novel therapeutic target in PD-specific pathologies.